Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06588257Phase 4Completed

Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study

Role: collaborator

NCT07357584Phase 4Not Yet Recruiting

Efficacy and Safety of Doravirine in the Rapid Initiation

Role: collaborator

NCT06951399Phase 2Not Yet Recruiting

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT06995157Not ApplicableRecruiting

Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination

Role: collaborator

NCT06700941Completed

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

Role: collaborator

NCT06675721Not Yet Recruiting

A Survey of Acceptance and Factors Associated With Hesitancy Vaccination in Northeast Brazil

Role: collaborator

NCT03557853Completed

Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab

Role: lead

NCT04253119Completed

ART First-line Treatment Durability in Russia

Role: lead

NCT05721092Completed

Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India

Role: collaborator

NCT05322083Unknown

HIV A6 Genome In ART Unsuccessful Patients On DOR

Role: collaborator

All 10 trials loaded